These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11890187)

  • 1. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
    Shiloh R; Zemishlany Z; Aizenberg D; Valevski A; Bodinger L; Munitz H; Weizman A
    Int Clin Psychopharmacol; 2002 Mar; 17(2):59-64. PubMed ID: 11890187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients.
    Grinshpoon A; Valevski A; Moskowitz M; Weizman A
    Eur Psychiatry; 2000 Sep; 15(6):388-90. PubMed ID: 11004734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study.
    Poyurovsky M; Koren D; Gonopolsky I; Schneidman M; Fuchs C; Weizman A; Weizman R
    Eur Neuropsychopharmacol; 2003 Mar; 13(2):123-8. PubMed ID: 12650957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
    Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
    Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.
    Miodownik C; Lerner V; Statsenko N; Dwolatzky T; Nemets B; Berzak E; Bergman J
    Clin Neuropharmacol; 2006; 29(2):68-72. PubMed ID: 16614537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.
    Zoccali R; Muscatello MR; Cedro C; Neri P; La Torre D; Spina E; Di Rosa AE; Meduri M
    Int Clin Psychopharmacol; 2004 Mar; 19(2):71-6. PubMed ID: 15076014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
    Pickar D; Bartko JJ
    Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.
    Hayashi T; Yokota N; Takahashi T; Tawara Y; Nishikawa T; Yano T; Furutani M; Fujikawa T; Horiguchi J; Yamawaki S
    Int Clin Psychopharmacol; 1997 Jul; 12(4):199-205. PubMed ID: 9347380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Meltzer HY; Elkis H; Vanover K; Weiner DM; van Kammen DP; Peters P; Hacksell U
    Schizophr Res; 2012 Nov; 141(2-3):144-52. PubMed ID: 22954754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
    Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
    Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
    Poyurovsky M; Shardorodsky M; Fuchs C; Schneidman M; Weizman A
    Br J Psychiatry; 1999 Mar; 174():238-42. PubMed ID: 10448449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.